Keywords: knoll, comarket, novartis, exelon, germany, pharmaceuticals, co-market
Knoll to comarket Novartis' Exelon is Germany
Article | 19 August 1999
- Knoll Pharmaceuticals is to co-market Novartis' Exelon(rivastigmine) in Germany, reports AFX News. The anti-Alzheimer's drug was first approved in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
